Other News

Rapid Medical Announces FDA Approval of Novel Temporary Aneurysm Embolization Assist Device

YOKNEAM, Israel, May 7, 2019 /PRNewswire/ — Rapid Medical, a company focused on the development of next generation neurovascular devices, today announced that its Comaneci device received FDA clearance as a Temporary Coil Embolization Assist Device. The Comaneci is the first and only device in a new category of temporary coil embolization assist devices. […]

Vytronus Reaches Enrollment Milestone in Clinical Trial of Automated Ultrasound Technology for Treatment of Persistent Atrial Fibrillation

SUNNYVALE, Calif., May 7, 2019 /PRNewswire/ — Vytronus, Inc., a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that its early feasibility study of automated ultrasound technology for the treatment of persistent atrial fibrillation recently passed the midpoint in patient enrollment and is on track […]

Corindus Equips the World’s First Fully Robotic Catheterization Laboratory

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Vascular Robotic Systems, making it the first hospital […]

Inari Medical Announces Publication of FLARE IDE Study Results

IRVINE, Calif., May 7, 2019 /PRNewswire/ — Inari Medical, Inc. announced today the publication of its 106-patient prospective multicenter FlowTriever Mechanical Pulmonary Embolectomy (FLARE) study for the treatment of intermediate-risk pulmonary embolism (PE).  The study was published in JACC: Cardiovascular Interventions.  FLARE was conducted under the direction of co-principal investigators, Dr. Kenneth Rosenfield, Section Head […]

BioSig Technologies Completes Patient Cases at Indiana University

Santa Monica, CA, May 06, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company conducted patient cases using the PURE EP(tm) System at Indiana […]

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin‑mediated amyloidosis

SILVER SPRING, Md., May 6, 2019 /PRNewswire/ — On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin‑mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the […]

Boston Scientific Receives U.S. FDA Approval for The VICI VENOUS STENT™ System

MARLBOROUGH, Mass., May 6, 2019 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked […]

Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

VANCOUVER, May 6, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that 1,000 patients diagnosed with refractory angina have been […]

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin‑mediated amyloidosis

SILVER SPRING, Md., May 6, 2019 /PRNewswire/ — On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin‑mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the […]